23andMe Investor Presentation Deck

Our I/O Programs Were Identified With ML and AI Applied to Our Proprietary I/O Genetic Signature Large I/O market with $60B in 2021 sales 2021 sales of leading checkpoint inhibitors KEYTRUDA $17.2B OPDIVO YERVOY $7.5B $2.0B 23andMe's proprietary I/O genetic signature developed with ML which also identifies marketed I/O drugs I/O genetic signature shows opposing effects on autoimmune and cancer phenotypes tonsillectomy- 11d- anti tn alpha or dmards- juvenile ttd- igb.dry skin froquancy- iodine treatment ever- hypothyroidism- hyperthyroidism hashimotos grines vitiago- iqb.dandruff frequency- celiac HLA all psoriasis rheumatoid arthrite look meds anti inf_alpha- thyroid removed- immunodeficiency squamous cell carcinoma - basal cell carcinoma actinic keratosis- non melanoma skin cancer- any skin cancer- Autoimmune Cancer We discovered additional targets that have a similar genetic I/O signature CD200R1 (23ME'610) CD96 (GSK'608) + others Copyright © 2023 23and Me, Inc. 23andMe 38

View entire presentation